Fig. 2: NR2E3 mutations are closely associated with cancer.
From: Orphan nuclear receptor NR2E3 is a new molecular vulnerability in solid tumors by activating p53
A NR2E3 mutations were enriched in colon cancer, uterus cancer and melanoma. Nonsynonymous SNVs of NR2E3 were counted in TCGA cancer database and “All of Us” reference database. Age, sex and race were considered. The age group cutoffs were set [53,54,55]. Chi-square test (two-tail, 1 df) and Woolf logit test (n > 99k) or Baptista-Pike (n < 99k) test were used to calculate the p values and OR values with 95% confidence interval only in the comparisons with minimal case number of 5. B NR2E3 SNVs differentially regulated p53 protein levels in HeLa cells two days after transfection with 1.2 µg of the indicated constructs in 6-cm dishes in immunoblotting assay. GFP: transfection reference. C NR2E3 SNVs differentially stimulated the p53RE-FLuc reporter in HeLa cells two days after transfection with 0.01 µg of the indicated constructs in 96-well plates. SV40-RLuc was used as the transfection reference. The relative FLuc activity in the empty vector control was normalized to 1. p value was calculated by one-way Anova test and Bonferroni post-hoc test (each mutation vs Con vs FL). *p < 0.0167; **p < 0.0033; ***p < 0.0003. D NR2E3 SNVs differentially regulated HeLa cell apoptosis two days after transfection with 1.2 µg of the indicated constructs in 6-cm dishes in Annexin V-binding assay. The apoptosis in the mock control was normalized to 1. p value was calculated by one-way Anova test and Bonferroni post-hoc test (each mutation vs Con vs FL). *p < 0.0167; **p < 0.0033; ***p < 0.0003. Mean ± SD shown in all the histograms.
